Jupiter Neurosciences, Inc. (JUNS) Research
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Market snapshot
- Symbol
- JUNS
- Price
- $0.24
- Day change
- +3.66%
- Market cap
- $8.7M
- P/E ratio
- -0.91x
- 52-week range
- 0.172-3.33
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
Recent news
- Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.
Peer companies
Recent insider activity
- Brady Allison W — A-Award (100000 shares) on 2026-06-02
- Elmasri Saleem — A-Award (525565 shares) on 2026-06-02
- ROSEN CHRISTER — A-Award (747783 shares) on 2026-06-02
- Hemmerly Nicholas H. — A-Award (100000 shares) on 2026-06-02
- Kampf Julie B. — A-Award (100000 shares) on 2026-06-02
Open Jupiter Neurosciences, Inc. (JUNS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.